JRGD:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - Global Research Enhanced Index Equity UCITS ETF - USD (dist) (EUR)

ETF | Others |

Last Closing

USD 43.865

Change

+0.15 (+0.34)%

Market Cap

USD 2.00M

Volume

7.08K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.23 (+0.49%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.37 (+0.38%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.19 (+0.81%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.01 (-0.11%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.03 (+0.56%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.01 (+0.02%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.02 (+0.19%)

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.06 (-0.10%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.13 (+1.34%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.24 (+0.20%)

USD 12.26B

ETFs Containing JRGD:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.44% 23% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.44% 25% F 25% F
Trailing 12 Months  
Capital Gain 7.55% 58% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.55% 59% D- 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.35% 64% D 64% D
Dividend Return 10.35% 63% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.34% 57% F 65% D
Risk Adjusted Return 91.24% 78% C+ 81% B-
Market Capitalization 2.00M 1% F 1% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.